Table 1.

Clinical trials of ROCK inhibitors.

Rock inhibitors	NCT number	Condition or disease	Intervention	Current phase
Y-27632	NCT05309135	Corneal edema	Drug: HCEC-1	Phase 1
CPL409116	NCT04670757	Healthy	Drug: oral CPL409116	Phase 1
Fasudil	NCT04734379	• Progressive supranuclear palsy • Corticobasal syndrome	Drug: oral fasudil	Phase 2
Fasudil	NCT04793659	Dementia	Drug: oral fasudil	Phase 2
Fasudil	NCT03753269	ST segment elevation myocardial infarction	Drug: fasudil hydrochloride	Phase 4
Fasudil	NCT00498615	Raynaud Scleroderma	Drug: oral tablets of fasudil	Phase 3
Fasudil	NCT03792490	Amyotrophic lateral sclerosis	Drug: fasudil IV solution	Phase 2
Fasudil	NCT04191954	Retinopathy of prematurity	Drug: fasudil eye drops	Phase 2
Fasudil	NCT03391219	Retinal vein occlusion	Drug: injection combined bevacizumab and fasudil	Phase 3
Fasudil	NCT01823081	Diabetic macular edema	Drug: intravitreal injection of fasudil and bevacizumab	Phase 3
Fasudil	NCT00120718	• Atherosclerosis • Hypercholesterolemia	Drug: fasudil	Phase 2
Fasudil	NCT03404843	Cardiovascular diseases	Drug: fasudil hydrochloride	Phase 2
Ripasudil	NCT04621136	Retinopathy of prematurity	Drug: ripasudil ophthalmic solution 0.4%	Phase 1 Phase 2
Ripasudil	NCT03813056	Fuchs endothelial dystrophy	Drug: glanatec Drug: optive, ophthalmic solution Procedure: descemet membrane endothelial keratoplasty	Phase 2
Ripasudil	NCT05528172	Corneal edema after cataract surgery	Drug: ripasudil	Phase 3
PHP-201	NCT04863365	• Primary open angle glaucoma • Ocular hypertension	Drug: placebo ophthalmic solution Drug: PHP-201 ophthalmic solution	Phase 2
Belumosudil	NCT04735822	Healthy	Drug: oral suspensions of belumosudil Drug: oral tablets of belumosudil	Early phase 1
INS-115644	NCT00443924	• Ocular hypertension • Open angle glaucoma	Drug: INS115644 ophthalmic solution	Phase 1
LX7101	NCT01528111	• Primary open-angle glaucoma • Ocular hypertension	Drug: LX7101	Phase 1 Phase 2

Note: To learn more about the studies above, refer to them using the ClinicalTrials.gov identifier (NCT number).